Your session is about to expire
← Back to Search
Aducanumab for Alzheimer's Disease
Study Summary
This trial is testing the safety and tolerability of aducanumab, a drug for Alzheimer's disease, over 100 weeks. There is a wash-out period for participants who have previously received aducanumab or placebo.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 148 Patients • NCT05108922Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have tested positive for HIV.It seems like the criterion you provided is incomplete. Could you please provide more details or context so that I can assist you better?You were taking part in a study for aducanumab when it was stopped early.I had a seizure between my last doctor's visit and now.I have no other health conditions causing my memory problems besides Alzheimer's.You are unable to have a brain MRI for medical reasons.I finished the initial study phase and handled the aducanumab treatment well.My liver isn't working properly, as shown by recent tests.I haven't had serious heart issues or a heart attack in the last year.I have not had a serious illness or infection in the last 30 days.I have not had a stroke or unexplained fainting in the last year.
- Group 1: Aducanumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Do you have an age limit for participants in this research?
"This specific medical trial is searching for individuals that are 50 years old or above, and younger than 90 years old."
When will Aducanumab receive full regulatory approval?
"Aducanumab was given a safety score of 3 by our team at Power. This is because Aducanumab is currently in Phase 3 trials, which implies that there is some evidence suggesting the medication's efficacy as well as multiple rounds of data affirming its safety."
Are there any other drugs that have been studied in combination with Aducanumab?
"Aducanumab was first researched at Wake Forest Baptist Health in 2020. So far, 5 studies have been completed while 2 are ongoing. These active trials are based in New york City."
Have other similar investigations been done in the past?
"Research into Aducanumab began in 2020 with a study sponsored by Biogen. After the initial Phase 3 clinical trial, which had 1696 participants, the drug received approval. As of now, there are 2 ongoing studies involving Aducanumab being conducted in 202 cities across 20 countries."
Are there specific individuals that this clinical trial is meant for?
"This trial is enrolling 1696 patients with Alzheimer's disease who are between the ages of 50 and 90. The following criteria must also be met: Participant was participating in an aducanumab clinical study at the time of the announcement of early termination (feeder studies)., Has one care partner who, in the Investigator's opinion, has adequate contact with the participant as to be able to provide accurate information about the participant's cognitive and functional abilities., Participant must have completed the Core study period (Week 102) and adequately tolerated 10 mg/kg of aducanumab during the Core study period in the opinion of"
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger